Zacks Research Has Weak Outlook for Omnicell FY2027 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Equities research analysts at Zacks Research dropped their FY2027 earnings estimates for Omnicell in a report issued on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $1.22 per share for the year, down from their previous estimate of $1.36. The consensus estimate for Omnicell’s current full-year earnings is $1.09 per share.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%.

OMCL has been the subject of several other research reports. Benchmark reissued a “buy” rating and issued a $62.00 price target on shares of Omnicell in a research report on Tuesday, February 4th. Bank of America reduced their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Omnicell presently has a consensus rating of “Hold” and an average price target of $52.33.

Omnicell Trading Down 1.1 %

Shares of Omnicell stock opened at $38.06 on Friday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The stock has a 50 day moving average price of $42.39 and a two-hundred day moving average price of $43.81. The stock has a market capitalization of $1.76 billion, a PE ratio of 140.97, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Insider Transactions at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 2.64% of the stock is owned by insiders.

Institutional Investors Weigh In On Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC grew its holdings in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock worth $35,000 after acquiring an additional 273 shares during the period. Johnson Financial Group Inc. purchased a new position in shares of Omnicell in the fourth quarter worth approximately $37,000. Van ECK Associates Corp boosted its holdings in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after buying an additional 315 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Omnicell in the 4th quarter worth approximately $53,000. Finally, First Horizon Advisors Inc. increased its holdings in Omnicell by 36.3% in the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after acquiring an additional 355 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.